EU Conditional Approval Should Be A Drug Development Tool, Not A Rescue Remedy
This article was originally published in SRA
Executive Summary
Pharmaceutical companies in the EU should see conditional marketing authorization as a useful drug development planning tool, rather than as a "rescue option" to be used when they are unable to secure a full marketing authorization because they have not generated the required additional data, according to a senior European Commission official.
New to Pink Sheet?
Start a free trial today!
Register for our free email digests:
Register for our free email digests:
